Improving outcomes of blood stem cell transplants
Developing novel therapies to improve blood stem cell transplantation outcomes
This study is looking at a protein called EGFL7 to see if it can help make blood stem cell transplants safer by reducing a serious complication where the donor's immune cells attack the recipient's body, which could lead to better outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10913622 on NIH RePORTER |
What this research studies
This research focuses on enhancing the success of blood stem cell transplants by investigating a protein called EGFL7, which may help reduce the severity of acute graft-versus-host disease (aGVHD). aGVHD is a serious complication where donor immune cells attack the recipient's tissues. The researchers aim to understand how increasing levels of EGFL7 can prevent this harmful immune response by inhibiting the activation of blood vessel cells and reducing inflammation. By using animal models, they will test the effectiveness of a treatment involving recombinant EGFL7 to see if it can improve transplant outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing allogeneic hematopoietic stem cell transplantation who are at risk for acute graft-versus-host disease.
Not a fit: Patients who are not undergoing stem cell transplantation or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective blood stem cell transplants, reducing the risk of severe complications for patients.
How similar studies have performed: Previous research has shown promise in using similar approaches to modulate immune responses in transplant settings, indicating potential for success in this area.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Garzon, Ramiro — University of Utah
- Study coordinator: Garzon, Ramiro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.